

Emergent BioSolutions acquires Adapt Pharma

19 October 2018 | News

Total cost of the transaction was \$635 million (\$575 million in cash, \$60 million in Emergent common stock), with the potential for up to an additional \$100 million in cash for sales-based milestones through 2022.



Adapt Pharma, maker of the naloxone nasal spray Narcan used for the emergency treatment of known or suspected opioid overdoses, has been acquired by Emergent BioSolutions Inc. in a deal announced this week. Emergent will bring on about 50 employees in the U.S., Canada and Ireland as part of the deal.

The total cost of the transaction was \$635 million (\$575 million in cash, \$60 million in Emergent common stock), with the potential for up to an additional \$100 million in cash for sales-based milestones through 2022.

Narcan is a natural fit for the portfolio of Emergent, a global life sciences company that focuses on specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats.

In the news release announcing the transaction, Doug White, senior vice president and Devices Business Unit head at Emergent, said the company is “committed to expanding awareness and availability of this convenient, easy-to-administer life-saving treatment by combining Adapt Pharma’s efforts with state and local governments, first responders, pharmacies, and other channels, with Emergent’s 20-year track record as a trusted partner to the federal government.”